Search

BioNTech SE ADR

Cerrado

SectorSanidad

92.98 0.85

Resumen

Variación precio

24h

Actual

Mínimo

89.88

Máximo

93.19

Métricas clave

By Trading Economics

Ingresos

-294M

-834M

Ventas

-13M

107M

BPA

-3.03

Margen de beneficios

-777.273

Empleados

7,807

EBITDA

-32M

-482M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+33.83% upside

Dividendos

By Acuity

Próximas Ganancias

3 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-17M

23B

Apertura anterior

92.13

Cierre anterior

92.98

Noticias sobre sentimiento de mercado

By Acuity

19%

81%

51 / 340 Clasificación en Healthcare

BioNTech SE ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 ago 2026, 19:26 UTC

BioNTech SE shares are higher today, continuing an upward trend since Thursday. This movement occurs despite concerns over declining U.S. retail sales data.

13 ago 2026, 19:21 UTC

News

BioNTech SE shares are lower as analysts adjust price targets following a significant second-quarter revenue decline and a net loss of €820.8 million.

12 ago 2026, 19:26 UTC

Correlated Moves

BioNTech SE's shares are higher today, supported by a significant rise in Moderna Inc. amid optimistic market sentiment following recent inflation data.

11 ago 2026, 20:06 UTC

BioNTech SE shares are near unchanged amid a flat market performance. The stock remains above its 20-day moving average and near the upper end of its one-month range.

10 ago 2026, 21:01 UTC

BioNTech SE shares are higher in after-market trading, showing stability despite broader market conditions and weaker-than-expected job growth data.

7 ago 2026, 19:56 UTC

News
Correlated Moves

BioNTech SE is trading higher, likely influenced by Moderna's significant gains. The stock remains above its 20-day moving average despite recent revenue declines.

6 ago 2026, 19:51 UTC

News
Correlated Moves

BioNTech SE shares are lower amid negative sentiment in the Biotechnology sector, following a revenue decline and CEO transition announcement.

5 ago 2026, 19:32 UTC

News

BioNTech SE shares are higher today after Citigroup maintained its Buy rating, lowering its price target to $125 while Evercore ISI kept its Outperform rating at $130.

4 ago 2026, 20:03 UTC

News
Social Media

BioNTech SE reported a widened second-quarter loss and lowered 2026 revenue guidance, contributing to shares trading lower since Monday's close.

3 ago 2026, 21:01 UTC

BioNTech SE shares are lower in after-market hours, showing little movement despite a broader market rally and investor optimism from lower oil prices.

31 jul 2026, 19:16 UTC

Correlated Moves

BioNTech SE shares are lower today, pressured by broader market sentiment and a decline in Moderna Inc. The stock remains below its 20-day moving average.

30 jul 2026, 21:01 UTC

BioNTech SE shares are trading lower in after-market hours, reversing earlier gains and reflecting notable volatility without any specific news to explain the movement.

29 jul 2026, 19:55 UTC

BioNTech SE shares are advancing during Wednesday's session, reaching a session high earlier today before pulling back slightly. No specific news was identified.

28 jul 2026, 19:16 UTC

BioNTech SE shares are advancing today, rebounding from earlier lows. The stock's resilience contrasts with declines in the Nikkei 225 Index.

27 jul 2026, 19:06 UTC

BioNTech SE shares are higher today amid positive market sentiment, reaching a peak earlier. No specific news has been identified to explain the movement.

24 jul 2026, 19:06 UTC

BioNTech SE shares are lower today, continuing a decline amid broader market pressure and a significant drop in crude oil prices.

22 jul 2026, 18:06 UTC

BioNTech SE shares are lower today, reflecting broader market caution amid rising crude oil prices and geopolitical tensions ahead of major technology earnings reports.

21 jul 2026, 14:41 UTC

News

BioNTech SE is rising amid positive market sentiment and plans to report second-quarter 2026 results on August 4, 2026. The Nasdaq 100 Index is also up.

20 jul 2026, 19:06 UTC

News

BioNTech SE shares are higher today, supported by a positive analyst outlook and an average recommendation of "Moderate Buy" from nineteen brokerage firms.

Comparación entre iguales

Cambio de precio

BioNTech SE ADR previsión

Precio Objetivo

By TipRanks

33.83% repunte

Estimación a 12 Meses

Media 124.58 USD  33.83%

Máximo 142 USD

Mínimo 92 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioNTech SE ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

10

Comprar

2

Mantener

0

Vender

Sentimiento

By Acuity

51 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac
help-icon Live chat